Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

BACKGROUND: Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP). The effect of inhibiting these transporters on tissue exposure to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Erin R, Smith, Nicola F, Figg, William D, Sparreboom, Alex
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717937/
https://www.ncbi.nlm.nih.gov/pubmed/19591692
http://dx.doi.org/10.1186/1756-9966-28-99

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717937/
https://www.ncbi.nlm.nih.gov/pubmed/19591692
http://dx.doi.org/10.1186/1756-9966-28-99

Ejemplares similares